CirCode Announces Research Agreement with Pfizer to Explore the Potential of Circular RNA Therapeuti

Shanghai, China – CirCode Biomed announced a research agreement with Pfizer Inc. to explore the potential of CirCode’s Circular RNA therapeutics technology.   The aim of the agreement is to deepen current knowledge of how to translate circular RNA technology into potential drug candidates and will make use of CirCode’s proprietary circular RNA platform and Pfizer’s broad expertise in drug discovery.